演題抄録

International Symposium

開催概要
開催回
第51回・2013年・京都
 

ROLES OF HBV AND HCV IN HCC IN GHANA

演題番号 : IS1-1

[筆頭演者]
Edwin Kwame Wiredu:1,2 
[共同演者]
Richard Harry Asmah:1、Isaac Boamah:3

1:Department of Med Lab Sciences, School of Allied Health Sciences, Univ of Ghana, Ghana、2:Dept of Pathology, UGMS, Ghana、3:Dept of Microbiology, UGMS, Ghana

 

Hepatocellular carcinoma (HCC) is the fifth most common cancer, the third most common cause for cancer death in the world, and responsible for close to one million deaths each year. It accounts for 85% to 90% of cases of primary liver cancer. There is vast amount of epidemiological evidence that persistent infection with hepatitis B virus (HBV) and hepatitis C (HCV) virus-induced fibrosis and cirrhosis are major risk factors for the development of HCC with estimated 50% and 25% of cases due to chronic HBV and HCV infection respectively. Worldwide geographic differences in incidence of HCC mirror differences in incidence of these two viruses. In Sub-Saharan Africa HCV prevalence is estimated to be 3.0%. Ghana reportedly has a mean/median Hepatitis C infection prevalence of around 1.7%, ranging between 1.3% and 8.4%.In general, HCC develops only after two or more decades of HBV or HCV infection. This paper seeks to share our experience in Ghana of the role of HBV and HCV in HCC in Ghana. In a study of 70 patients with chronic liver disease, 19 patients had HCC with 15 (79%) positive for HBsAg. Nine of the 15 positive cases could be genotyped after PCR. Using RFLP, 8 were found to be type E with 1 being type A. Six of the cases were HCV-positive (8.6%) with 1 case being HCC. The study shows that HCC in Ghana is predominantly related to HBV infection compared to HCV, which correlates with the greater prevalence of HBV infection.

前へ戻る